FGFR signaling is a potent driver of medulloblastoma (MB) progression, driving an invasive phenotype. We explored the impact of a short term bFGF stimulation in D425 MB cells on phosphoproteome level and studied the effect of pretreatment with the FRS2 targeting small molecule C7, or the MAP4K4 inhibitor Prostetin.